FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ington, D.C. 20549	
--------------------	--

OMB APPROVAL											
OMB Number:	3235-028										
H =											

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Estimated average burden hours per response 0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Culleton Bruce</u>					2. Issuer Name and Ticker or Trading Symbol PROKIDNEY CORP. [PROK]								(Ch	elationship o eck all applic Directo	able)	10	to Issu % Ow her (si	ner	
(Last)	(F OKIDNEY (irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/01/2023								below)	P, Clinical	be	low)	респу	
2000 FRONTIS PLAZA BOULEVARD, SUITE 250					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WINSTON- SALEM NC 27103													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	itate)	(Zip)		$ _{\sqcap}$	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 2											to		
		Tal	ole I - Non	-Deriva	ative	Se	curities	s Ac	quired, [Disp	osed c	of, or Be	eneficial	y Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ar)	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Dispo		Dispose	curities Acquired (A) o esed Of (D) (Instr. 3, 4		Beneficia Owned F	es ally following	6. Ownersh Form: Dire (D) or Indir (I) (Instr. 4)	ect E	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	mount (A) or (D)		Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
			Table II - D						uired, Di , options					Owned					
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			Co	ansact		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	Own Form Direct or Inc (I) (In		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode V		(A)		Date Exercisable		piration ite	Title	Amount or Number of Shares		(Instr. 4)	(6)			
Employee stock option (right to buy)	\$13.08	08/01/2023			A		485,000		(1)	08	/01/2033	Class A Ordinary Shares	485,000	\$0.00	485,000))		

Explanation of Responses:

 $1. \ The \ option \ vests \ 25\% \ on \ 1st \ anniversary \ of \ August \ 1, 2023 \ and \ the \ remaining \ 75\% \ vests \ in \ substantially \ equal \ monthly \ installments \ for \ 36 \ months \ thereafter.$

Remarks:

/s/ Todd Girolamo, attorney in

08/03/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.